Medtronic plc posted nearly 50% year-over-year growth in its cardiac ablation business this quarter, with a 72% increase in revenue in the U.S., largely driven by pulsed field ablation. With ...

Rates of adverse events (AEs) gave pause to some on Wall Street, and shares of Viking Therapeutics Inc. (NASDAQ:VKTX) fell 42%, or $17.73, to close Aug. 19 at $24.36 after the firm reported 13-week ...

CSL Ltd.’s stock tumbled 16.88% on the news that it plans to cut 3,000 jobs and to hive off its Seqirus vaccine unit in a cost-cutting measure to save more than $500 million per year over the next ...

Adding another name to an impressive roster of partners assembled over the past few years, Skyhawk Therapeutics Inc. inked a ...

Better Medicine OÜ raised €1 million (US$1.16 million) in a pre-seed funding round for its AI platform, Bmvision Kidney, ...

Remegen Co. Ltd.’s telitacicept (RC-18) met the primary endpoint in a phase III trial for treating primary Sjögren's syndrome (pSS), and the company plans to submit a BLA to China’s National Medical ...

Aussie gene therapy company Mirugen Pty Ltd. has emerged from stealth mode from the Center for Eye Research Australia in Melbourne, toting a AU$4.5 million (US$2.9 million) seed round that will see it ...

Superluminal Medicines Inc. and Eli Lilly and Co. are collaborating in a deal to develop cardiometabolic disease and obesity ...

Cptx GmbH’s QUIET-CAR collaborative project with Nanocell Therapeutics Inc. has been awarded a Eurostars Grant from the EU through the Horizon Europe program and Eureka Network. The QUIET-CAR project ...

Investigators at St. John’s University have published preclinical data regarding their endothelin-1 receptor (ETRA) antagonist HJP-272 for the potential treatment of cancer.

Mycobacterium abscessus, a nontuberculous mycobacterium, is a significant cause of chronic pulmonary infections, particularly in individuals with compromised immune systems or structural lung ...

Siteone Therapeutics Inc. has disclosed sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain.